Selected Cutaneous and Mucocutaneous Manifestations Associated with Inflammatory Bowel Disease: Diagnostic and Therapeutic Implications
DOI:
https://doi.org/10.12775/JEHS.2026.95.73808Keywords
Inflammatory Bowel Diseases; Crohn Disease; Colitis, Ulcerative; Skin Diseases; Erythema Nodosum; Pyoderma GangrenosumAbstract
Abstract
Inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, comprises chronic inflammatory disorders of the gastrointestinal tract. In addition to intestinal symptoms, IBD may be accompanied by numerous extraintestinal manifestations, including cutaneous and mucocutaneous lesions. The most commonly reported dermatological manifestations include erythema nodosum, pyoderma gangrenosum, and oral lesions associated with Crohn’s disease. Cutaneous manifestations may precede the diagnosis of IBD; therefore, their recognition is important not only for dermatologists, but also for specialists in internal medicine and gastroenterology. Early identification of these manifestations may contribute to earlier diagnosis of the underlying disease and implementation of appropriate treatment. This review discusses selected, clinically relevant cutaneous and mucocutaneous manifestations in the course of IBD, with particular emphasis on their epidemiology, diagnostic criteria, clinical presentation, and therapeutic options.
References
References
1. Antonelli E, Bassotti G, Tramontana M, Hansel K, Stingeni L, Ardizzone S, Genovese G, Marzano AV, Maconi G. Dermatological Manifestations in Inflammatory Bowel Diseases. J Clin Med. 2021 Jan 19;10(2):364. doi: 10.3390/jcm10020364. PMID: 33477990; PMCID: PMC7835974.
2. Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology. 2021 Oct;161(4):1118-1132. doi: 10.1053/j.gastro.2021.07.042. Epub 2021 Aug 3. PMID: 34358489; PMCID: PMC8564770.
3. Faggiani I, Fanizza J, D'Amico F, Allocca M, Zilli A, Parigi TL, Barchi A, Danese S, Furfaro F. Extraintestinal Manifestations in Inflammatory Bowel Disease: From Pathophysiology to Treatment. Biomedicines. 2024 Aug 13;12(8):1839. doi: 10.3390/biomedicines12081839. PMID: 39200303; PMCID: PMC11351332.
4. He R, Zhao S, Cui M, Chen Y, Ma J, Li J, Wang X. Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations. Front Immunol. 2023 Oct 26;14:1234535. doi: 10.3389/fimmu.2023.1234535. PMID: 37954590; PMCID: PMC10637386.
5. Pellicer Z, Santiago JM, Rodriguez A, Alonso V, Antón R, Bosca MM. Management of cutaneous disorders related to inflammatory bowel disease. Ann Gastroenterol. 2012;25(1):21-26. PMID: 24713996; PMCID: PMC3959344.
6. Ungureanu L, Cosgarea R, Alexandru Badea M, Florentina Vasilovici A, Cosgarea I, Corina Șenilă S. Cutaneous manifestations in inflammatory bowel disease (Review). Exp Ther Med. 2020 Jul;20(1):31-37. doi: 10.3892/etm.2019.8321. Epub 2019 Dec 12. PMID: 32508989; PMCID: PMC7271697.
7. Hung YT, Le PH, Kuo CJ, Tang YC, Chiou MJ, Chiu CT, Kuo CF, Huang YH. The Temporal Relationships and Associations between Cutaneous Manifestations and Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study. J Clin Med. 2021 Mar 22;10(6):1311. doi: 10.3390/jcm10061311. PMID: 33810197; PMCID: PMC8004605.
8. Fedor I, Zold E, Barta Z. Temporal Relationship of Extraintestinal Manifestations in Inflammatory Bowel Disease. J Clin Med. 2021 Dec 20;10(24):5984. doi: 10.3390/jcm10245984. PMID: 34945280; PMCID: PMC8708470.
9. Malik TF, Aurelio DM. Extraintestinal Manifestations of Inflammatory Bowel Disease. 2023 Mar 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. PMID: 33760556.
10. Aberumand B, Howard J, Howard J. Metastatic Crohn's Disease: An Approach to an Uncommon but Important Cutaneous Disorder. Biomed Res Int. 2017;2017:8192150. doi: 10.1155/2017/8192150. Epub 2017 Jan 3. PMID: 28127561; PMCID: PMC5239966.
11. Pecci-Lloret MP, Ramirez-Santisteban E, Hergueta-Castillo A, Guerrero-Gironés J, Oñate-Sánchez RE. Oral Manifestations of Crohn's Disease: A Systematic Review. J Clin Med. 2023 Oct 10;12(20):6450. doi: 10.3390/jcm12206450. PMID: 37892587; PMCID: PMC10607549.
12. Downey K, Zhang R, Ortega-Loayza AG. Pyoderma Gangrenosum and Inflammatory Bowel Disease: Recent Insights into Epidemiology, Pathogenesis, and Therapeutic Approaches. J Inflamm Res. 2025 Nov 12;18:15859-15873. doi: 10.2147/JIR.S540840. PMID: 41255587; PMCID: PMC12620507.
13. Sasson S, Kalisky I, Rosenfeld G, Kiow JLC, Bressler B. Erythema nodosum as a marker for objective disease activity in inflammatory bowel disease. Crohns Colitis 360. 2026 Feb 20;8(1):otag013. doi: 10.1093/crocol/otag013. PMID: 41788361; PMCID: PMC12958114.
14. Rahvar M, Kerstetter J. Cutaneous manifestation of gastrointestinal disease. J Gastrointest Oncol. 2016 Apr;7(Suppl 1):S44-54. doi: 10.3978/j.issn.2078-6891.2015.059. PMID: 27034812; PMCID: PMC4783618.
15. Firek A, Warren K, Lorenzen C, Bonilla Md LP. Pyoderma Gangrenosum in Inflammatory Bowel Disease: A Rare Case Involving Mandibular, Elbow, and Pubic Ulcers. J Brown Hosp Med. 2024 Jan 1;3(1):90522. doi: 10.56305/001c.90522. PMID: 40027386; PMCID: PMC11864381.
16. Sleiman J, Hitawala AA, Cohen B, Falloon K, Simonson M, Click B, Khanna U, Fernandez AP, Rieder F. Systematic Review: Sweet Syndrome Associated with Inflammatory Bowel Disease. J Crohns Colitis. 2021 Nov 8;15(11):1864-1876. doi: 10.1093/ecco-jcc/jjab079. PMID: 33891004; PMCID: PMC8675328.
17. Sleiman J, Patel M, Khan MZ, Falloon K, Cohen B, Click B, Khanna U, Fernandez AP, Rieder F. Sweet Syndrome Associated with Active Inflammatory Bowel Disease: A Case Series of a Rare Extra-intestinal Manifestation. Dig Dis Sci. 2023 Sep;68(9):3562-3568. doi: 10.1007/s10620-023-07983-5. Epub 2023 Jul 5. PMID: 37402983; PMCID: PMC10921822.
18. Chrcanovic BR, Martins-Chaves RR, Pontes FSC, Fonseca FP, Pontes HAR, Gomez RS. Pyodermatitis-pyostomatitis vegetans: a case report and systematic review focusing on oral involvement. Oral Maxillofac Surg. 2024 Sep;28(3):1405-1414. doi: 10.1007/s10006-024-01234-1. Epub 2024 Mar 12. PMID: 38467949; PMCID: PMC11330387.
19. Bezzio C, Cavalli CAM, Franchellucci G, Dal Buono A, Gabbiadini R, Scalvini D, Manara S, Narcisi A, Armuzzi A, Saibeni S. Psoriasis and inflammatory bowel disease: concomitant IMID or paradoxical therapeutic effect? A scoping review on anti-IL-12/23 and anti-IL-23 antibodies. Ther Adv Gastroenterol. 2024 Nov 21;17:17562848241299564. doi: 10.1177/17562848241299564. PMID: 39575159; PMCID: PMC11580083.
20. Fu Y, Lee CH, Chi CC. Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol. 2018 Dec 1;154(12):1417-1423. doi: 10.1001/jamadermatol.2018.3631. PMID: 30422277; PMCID: PMC6583370.
21. Nehring P, Przybyłkowski A. Is Psoriasis Treatment a Risk Factor for Inflammatory Bowel Disease? Pharmaceut Med. 2020 Aug;34(4):257-262. doi: 10.1007/s40290-020-00340-1. PMID: 32514931; PMCID: PMC7427703.
22. Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, Lapins J, Matusiak L, Prens EP, Revuz J, Schneider-Burrus S, Szepietowski JC, van der Zee HH, Jemec GB. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015 Apr;29(4):619-44. doi: 10.1111/jdv.12966. Epub 2015 Jan 30. PMID: 25640693.
23. Mpakogiannis K, Fousekis FS, Karampinis E, Mastoridou E, Gaitanis G, Katsanos KH. Unravelling the Link Between Hidradenitis Suppurativa and Inflammatory Bowel Disease: A Literature Review. Biomedicines. 2025 Jul 27;13(8):1833. doi: 10.3390/biomedicines13081833. PMID: 40868088; PMCID: PMC12383343.
24. Chen WT, Chi CC. Association of Hidradenitis Suppurativa With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol. 2019 Sep 1;155(9):1022-1027. doi: 10.1001/jamadermatol.2019.0891. PMID: 31290938; PMCID: PMC6625071.
25. Phan K, Tatian A, Woods J, Cains G, Frew JW. Prevalence of inflammatory bowel disease (IBD) in hidradenitis suppurativa (HS): systematic review and adjusted meta-analysis. Int J Dermatol. 2020 Feb;59(2):221-228. doi: 10.1111/ijd.14697. Epub 2019 Oct 20. PMID: 31631340.
26. Garg A, Hsiao J, Porter ML, Shi V. Current Treatments and Future Directions for Hidradenitis Suppurativa: a Narrative Review of Completed and Ongoing Phase 3 Clinical Trials of Biologic Therapies. Dermatol Ther (Heidelb). 2025 Sep;15(9):2361-2377. doi: 10.1007/s13555-025-01487-y. Epub 2025 Jul 18. PMID: 40681937; PMCID: PMC12354412.
27. Lambert JLW, De Schepper S, Speeckaert R. Cutaneous Manifestations in Biological-Treated Inflammatory Bowel Disease Patients: A Narrative Review. J Clin Med. 2021 Mar 3;10(5):1040. doi: 10.3390/jcm10051040. PMID: 33802483; PMCID: PMC7959457.
28. Wong CY, Chu DH. Cutaneous signs of nutritional disorders. Int J Womens Dermatol. 2021 Sep 22;7(5Part A):647-652. doi: 10.1016/j.ijwd.2021.09.003. PMID: 35024418; PMCID: PMC8721081.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Magda Marciniak, Sviatlana Filitaryna, Monika Wiatr, Cezary Orzechowski, Michał Gutowski, Monika Kałwak, Aleksandra Foryś, Wojciech Wojas, Justyna Żabicka, Kinga Lichtarska, Patryk Dłubis
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 818
Number of citations: 0
